Drais Pharmaceuticals and Unibioscreen partner to develop new cancer drug
Under the terms of the agreement, Unibioscreen will receive upfront, development and regulatory milestones payments up to $31 million, in addition to commercial milestone payments. The license grants
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.